Belite Bio Receives FDA Breakthrough Therapy Designation for Tinlarebant in Treating Stargardt Disease
21/5 09:10
FDA grants Breakthrough Therapy Designation to Tinlarebant for Stargardt disease, based on promising Phase 3 trial results....
|
|
|
21/5 09:10
FDA grants Breakthrough Therapy Designation to Tinlarebant for Stargardt disease, based on promising Phase 3 trial results....